Yorvipath
- Prescription status not stated
- Hormones, such as thyroid and steroids
- Active substance
- Palopegteriparatide
- Made by
- Ascendis Pharma Bone Diseases A/S
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Yorvipath). It describes the substance, not this exact product.
At physiological conditions, palopegteriparatide releases PTH(1-34) to maintain a continuous systemic exposure.
Endogenous PTH maintains extracellular calcium and phosphate homeostasis by increasing serum calcium and decreasing serum phosphate.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-12
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Ascendis Pharma Bone Diseases A/S |
|---|---|
| Active substance | Palopegteriparatide |
| Used in | Hormones, such as thyroid and steroids |
| Classification | H05AA · Hormones, such as thyroid and steroids |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2023-11-17 |
| Last updated by the regulator | 2025-06-20 |
| EMA product number | EMEA/H/C/005934 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).